Bronchiolitis Obliterans Syndrome Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Bronchiolitis Obliterans Syndrome Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Bronchiolitis Obliterans Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Bronchiolitis Obliterans Syndrome Market with DelveInsight's In-Depth Report @ Bronchiolitis Obliterans Syndrome Market Size- https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Bronchiolitis Obliterans Syndrome Market Report
• In 2024, EU4 and the UK together accounted for more than 14 thousand diagnosed prevalent cases of BOS, a number expected to increase by 2034. Among these countries, Germany reported the highest number of diagnosed prevalent BOS cases in 2024.
• According to DelveInsight's analysts, there were more than 1,000 Grade 0 or 0p, over 400 Grade 1 (mild), more than 500 Grade 2 (moderate), and over 400 Grade 3 (severe) BOS cases in Japan in 2024, and these numbers are expected to increase during the forecast period (2025-2034).
• According to the World Health Organization's Global Observatory on Donation and Transplantation (GODT), nearly 3,000 lung transplants were performed in the US in 2024, all from deceased donors, underscoring the continued high demand for donor lungs and the vital importance of transplantation in treating advanced lung diseases.
• The leading Bronchiolitis Obliterans Syndrome Companies such as Zambon Pharma, GlaxoSmithKline, Incyte Corporation, Mereo Biopharma, Genentech, and others.
• Promising Bronchiolitis Obliterans Syndrome Therapies such as ARINA-1, Belumosudil, Fluticasone, Azithromycin, LAM-001, Ruxolitinib, and others.

Stay ahead in the Bronchiolitis Obliterans Syndrome Therapeutics Market with DelveInsight's Strategic Report @ Bronchiolitis Obliterans Syndrome Market Outlook- https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bronchiolitis Obliterans Syndrome Epidemiology Segmentation in the 7MM
• Total Bronchiolitis Obliterans Syndrome Diagnosed Prevalent Cases
• Bronchiolitis Obliterans Syndrome Grade-specific Cases
• Total Bronchiolitis Obliterans Syndrome Treated Cases

Download the report to understand which factors are driving Bronchiolitis Obliterans Syndrome epidemiology trends @ Bronchiolitis Obliterans Syndrome Prevalence- https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Bronchiolitis Obliterans Syndrome Emerging Drugs Profile
• ARINA-1: Renovion
ARINA-1 is an innovative, at-home nebulized therapy in Phase III development, designed to support overall lung health by effectively clearing excess mucus, reducing airway inflammation, and limiting bacterial growth. By combining these actions, ARINA-1 aims to improve breathing, protect lung function, and offer patients a convenient and proactive way to manage chronic lung conditions.

• Alvelestat (MPH966): Mereo Biopharma
Alvelestat developed by Mereo BioPharma, is an oral neutrophil elastase inhibitor currently being evaluated in Phase I/II clinical trials for patients with BOS following stem-cell transplantation. This investigational therapy represents a novel approach aimed at managing inflammation and slowing disease progression in individuals affected by BOS, where effective treatment options remain limited.

• LAM-001: OrphAI Therapeutics
LAM-001 is OrphAI Therapeutics' proprietary dry powder inhaled formulation of sirolimus. It is designed to deliver therapeutic doses directly to the lungs, minimizing systemic exposure and toxicity for a safer, more targeted treatment. Early animal and human data support this improved safety profile. LAM-001 is currently in Phase II clinical trials for rare lung diseases, including PH and BOS.

Bronchiolitis Obliterans Syndrome Therapeutics Market
The treatment landscape for BOS has progressed to focus on slowing progression, preserving lung function, and managing symptoms. Care centers on optimizing immunosuppression and supportive measures to control inflammation and complications. For advanced cases, retransplantation may be an option, highlighting the critical need for more effective therapies to improve long-term outcomes.

Bronchiolitis Obliterans Syndrome Treatment Market
The BOS treatment market is gradually expanding with a pipeline of promising therapies aiming to address the unmet need for targeted, lung-specific treatments that go beyond traditional immunosuppression. Emerging therapies include ARINA-1, an innovative nebulized therapy designed to restore lung health by clearing mucus and reducing airway inflammation; Alvelestat (MPH966), an oral neutrophil elastase inhibitor targeting neutrophil-driven damage; and LAM-001, an inhaled formulation of sirolimus engineered to deliver anti-inflammatory effects directly to the lungs while minimizing systemic toxicity. Several of these candidates have secured Fast Track or Orphan Drug Designations from the US FDA, reflecting their potential to transform BOS care by tackling the underlying mechanisms of chronic rejection and airway injury, and offering new hope for patients facing this progressive condition.

Bronchiolitis Obliterans Syndrome Market Outlook
BOS is the most common form of chronic lung allograft dysfunction, characterized by progressive and irreversible airflow obstruction due to fibrotic narrowing of the small airways. While its exact mechanism is not fully understood, BOS is believed to result from an alloimmune response in which the recipient's immune system attacks the transplanted lung, causing inflammation and scarring of the bronchioles. This immune-mediated injury is driven by persistent rejection processes and other factors like infections or gastroesophageal reflux, which further damage the airway epithelium. Over time, this leads to obliteration of the bronchiolar lumen, resulting in declining lung function and respiratory failure if untreated. Although there is no cure for BOS, management focuses on slowing disease progression by optimizing immunosuppression, using anti-inflammatory agents like azithromycin, and treating contributing factors, but these measures do not reverse established fibrosis. In advanced cases, lung retransplantation may be the only option to restore lung function and prolong survival.

Get In-Depth Knowledge on Bronchiolitis Obliterans Syndrome Market Trends and Forecasts with DelveInsight @ Bronchiolitis Obliterans Syndrome Treatment Market- https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Bronchiolitis Obliterans Syndrome Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Bronchiolitis Obliterans Syndrome Companies- Zambon Pharma, GlaxoSmithKline, Incyte Corporation, Mereo Biopharma, Genentech, and others.
• Bronchiolitis Obliterans Syndrome Therapies- ARINA-1, Belumosudil, Fluticasone, Azithromycin, LAM-001, Ruxolitinib, and others.
• Bronchiolitis Obliterans Syndrome Market Dynamics: Bronchiolitis Obliterans Syndrome Market Drivers and Barriers
• Bronchiolitis Obliterans Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives

Unlock Strategic Insights with DelveInsight's Comprehensive Bronchiolitis Obliterans Syndrome Market Report @ Bronchiolitis Obliterans Syndrome Market Drivers and Barriers- https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Bronchiolitis Obliterans Syndrome (BOS) Market Overview at a Glance
4. Executive Summary of Bronchiolitis Obliterans Syndrome (BOS)
5. Bronchiolitis Obliterans Syndrome Epidemiology and Market Methodology
6. Disease Background and Overview
7. Bronchiolitis Obliterans Syndrome Epidemiology and Patient Population
8. Bronchiolitis Obliterans Syndrome Patient Journey
9. Key Endpoints in Bronchiolitis Obliterans Syndrome (BOS) Clinical Trials
10. Emerging Bronchiolitis Obliterans Syndrome Therapies
11. Bronchiolitis Obliterans Syndrome: 7 Major Market Analysis
12. Bronchiolitis Obliterans Syndrome Market Access and Reimbursement
13. Bronchiolitis Obliterans Syndrome KOL Views
14. SWOT Analysis
15. Bronchiolitis Obliterans Syndrome Unmet Needs
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

About Us

DelveInsight is a leading focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and pharma sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.